Vivos Therapeutics, Inc. (NASDAQ:VVOS) Sees Large Decrease in Short Interest

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the target of a large drop in short interest in the month of March. As of March 15th, there was short interest totalling 249,000 shares, a drop of 27.6% from the February 28th total of 344,000 shares. Currently, 5.4% of the company’s stock are sold short. Based on an average daily trading volume, of 210,600 shares, the days-to-cover ratio is currently 1.2 days.

Hedge Funds Weigh In On Vivos Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VVOS. Cutter & CO Brokerage Inc. purchased a new stake in shares of Vivos Therapeutics during the fourth quarter worth about $163,000. Commonwealth Equity Services LLC grew its stake in Vivos Therapeutics by 23.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 26,000 shares of the company’s stock valued at $112,000 after purchasing an additional 5,000 shares in the last quarter. Geode Capital Management LLC increased its holdings in Vivos Therapeutics by 55.6% during the 4th quarter. Geode Capital Management LLC now owns 44,827 shares of the company’s stock worth $192,000 after purchasing an additional 16,025 shares during the last quarter. Finally, Anson Funds Management LP acquired a new position in shares of Vivos Therapeutics in the 4th quarter valued at approximately $1,041,000. 26.35% of the stock is owned by hedge funds and other institutional investors.

Vivos Therapeutics Stock Down 8.4 %

NASDAQ VVOS opened at $2.85 on Tuesday. Vivos Therapeutics has a fifty-two week low of $1.91 and a fifty-two week high of $6.28. The business has a 50 day moving average price of $3.72 and a two-hundred day moving average price of $3.61. The stock has a market cap of $16.79 million, a PE ratio of -0.50 and a beta of 7.47.

Vivos Therapeutics (NASDAQ:VVOS) last announced its earnings results on Thursday, March 27th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.15. Vivos Therapeutics had a negative net margin of 86.19% and a negative return on equity of 335.04%. Sell-side analysts anticipate that Vivos Therapeutics will post -1.79 EPS for the current fiscal year.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.